Memantine, an NMDA Antagonist, Prevents the Development of Hyperthermia in an Animal Model for Serotonin Syndrome

 

 Buy Article Permissions and Reprints

Background: Serotonin (5-HT) syndrome is the most serious side effect of antidepressants. Although several drugs have been used for the treatment of 5-HT syndrome, a universal pharmacotherapy has not been established. NMDA receptor antagonists have been reported to have neuroprotective effects. In the present study, the efficacy of NMDA antagonists, including memantine and MK-801, and potent 5-HT_2A antagonists, including risperidone and ketanserin, was evaluated in a 5-HT syndrome animal model. Methods: 5-Hydroxy-l-tryptophan (100 mg/kg) and clorgyline (2 mg/kg) were administered intraperitoneally in rats to induce 5-HT syndrome. The rectal temperature of the rats was measured, and the noradrenaline (NA) and 5-HT levels in the anterior hypothalamus were measured using a microdialysis technique. Results: In the group pretreated with saline, the rectal temperature increased to more than 40 °C, and all of the animals died within 90 min of the drug’s administration. The NA and 5-HT levels in the anterior hypothalamus increased to about 15- and 1100-fold of the pre-administration levels, respectively. Pretreatment with risperidone (0.5 mg/kg) and ketanserin (5 mg/kg) prevented the development of hyperthermia and the increase in the NA level. Memantine (10 mg/kg) and MK-801 (0.5 mg/kg) also prevented the development of hyperthermia and the increase in the NA level. These results suggest that NMDA antagonists, as well as potent 5-HT_2A antagonists, may be effective drugs for the treatment of 5-HT syndrome. Conclusions: Since memantine is clinically well tolerated, this drug is a particularly promising therapeutic drug for 5-HT syndrome treatment.

References

• 1 Bhushan B, Seth S D, Saxena S, Gupta Y K, Karmarkar M G. An adverse reaction to L-5-hydroxytryptophan.  Am J Psychiat. 1991;  148 268-269
  PubMedGoogle Scholar
• 2 Block F, Schwarz M. Memantine reduces functional and morphological consequences induced by global ischemia in rats.  Neurosci Lett. 1996;  208 41-44
  CrossrefPubMedGoogle Scholar
• 3 Bottlender R, Jäger M, Hofschuster E, Dobmeier P, Möller H J. Neuroleptic malignant syndrome due to atypical neuroleptics: three episodes in one patient.  Pharmacopsychiatry. 2002;  35 119-121
  Article in Thieme ConnectPubMedGoogle Scholar
• 4 Buchberger R, Wagner W. fluvoxamine: safety profile in extensive post-marketing surveillance.  Pharmacopsychiatry. 2002;  35 101-108
  Article in Thieme ConnectPubMedGoogle Scholar
• 5 Caroff S N, Mann S C, Campbell E C. Atypical antipsychotics and neuroleptic malignant syndrome.  Psychiat Ann. 2000;  30 314-321
  PubMedGoogle Scholar
• 6 Carroll B T. A common pathogenesis of the serotonin syndrome, catatonia, and neuroleptic malignant syndrome.  J Neuropsychiat Clin Neurosci. 2001;  13 150
  PubMedGoogle Scholar
• 7 De Ceballos M L, Benedi A, Urdin C, Del Rio J. Prenatal exposure of rats to antidepressant drugs down-regulates beta-adrenoceptors and 5-HT₂ receptors in cerebral cortex.  Neuropharmacology. 1985;  24 947-952
  CrossrefPubMedGoogle Scholar
• 8 Demirkiran M, Jankovic J, Dean J M. Ecstasy intoxication: an overlap between serotonin syndrome and neuroleptic malignant syndrome.  Clincal Neuropharmacol. 1996;  19 157-164
  PubMedGoogle Scholar
• 9 Fink M. Toxic serotonin syndrome or neuroleptic malignant syndrome? Case report.  Pharmacopsychiatry. 1996;  39 159-161
  PubMedGoogle Scholar
• 10 Green A R. 5-HT-mediated behavior animal studies.  Neuropharmacology. 1984;  23 1521-1528
  CrossrefPubMedGoogle Scholar
• 11 Hilton S E, Maradit H, Moller H J. Serotonin syndrome and drug combinations: focus on MAOI and RIMA.  Eur Arch Psychiat Neurosci. 1997;  247 113-119
  PubMedGoogle Scholar
• 12 Keck P E, Arnold L M. The serotonin syndrome.  Psychiat Ann. 2000;  30 333-343
  PubMedGoogle Scholar
• 13 Kline S S, Mauro L S, Scala-Barnet D M, Zick D. Serotonin syndrome versus neuroleptic malignant syndrome as a cause of death.  Clin Pharm. 1989;  8 510-514
  PubMedGoogle Scholar
• 14 Kornhuber J, Weller M, Schoppmeyer K, Riederer P. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties.  J Neural Transm (suppl). 1994;  43 91-104
  PubMedGoogle Scholar
• 15 Kornhuber J, Weller M. Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy.  Biol Psychiat. 1997;  41 135-144
  PubMedGoogle Scholar
• 16 Leysen J E, Gommeren W, Eens A, De Chaffoy De Courcelles D, Stoof J C, Janssen P AJ. Biochemical profile of risperidone, a new antipsychotic.  J Pharmacol Exp Ther. 1988;  247 661-670
  PubMedGoogle Scholar
• 17 Mann S C, Caroff S N, Fricchione G, Campbell E C. Central dopamine hypoactivity and the pathogenesis of neuroleptic malignant syndrome.  Psychiat Ann. 2000;  30 363-374
  PubMedGoogle Scholar
• 18 Mazzola-Pomietto P, Aulakh C S, Wozniak K M, Hill J L, Murphy J L. Evidence that 1-(2,5-dimethoxy-4-iodophenyl)-2-amono-propane (DOI)-induced hyperthermia in rats is mediated by stimulation of 5-HT_2A receptors.  Psychopharmacology. 1995;  117 193-199
  PubMedGoogle Scholar
• 19 Mills K C. Serotonin syndrome.  Criti Care Clin. 1997;  13 763-783
  PubMedGoogle Scholar
• 20 Nisijima K, Yoshino T, Ishiguro T. Risperidone counteracts lethality in an animal model of the serotonin syndrome.  Psychopharmacology. 2000;  150 9-14
  CrossrefPubMedGoogle Scholar
• 21 Nisijima K, Yoshino T, Yui K, Katoh S. Potent serotonin (5-HT)_2A receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome.  Brain Res. 2001;  890 23-31
  CrossrefPubMedGoogle Scholar
• 22 O’Connell M T, Sarna G S, Curzon G. Evidence for postsynaptic mediation of the hypothermic effect of 5-HT_1A receptor activation.  Br J Pharmacol. 1992;  106 603-609
  PubMedGoogle Scholar
• 23 Parsons C G, Danysz W, Quack G. Memantine is a clinically well-tolerated N-methyl-D aspartate (NMDA) receptor antagonist-a review of preclinical data.  Neuropharmacology. 1999;  38 735-767
  CrossrefPubMedGoogle Scholar
• 24 Paxinos G, Watson C. In: 2nd Edition, The rat brain in stereotaxic coordinates. Academic Press New York; 1986
  Google Scholar
• 25 Rao V L, Dogan A, Todd K G, Bowen K K, Dempsey R J. Neuroprotection by memantine, a non-competitive NMDA receptor antagonist after traumatic brain injury in rats.  Brain Res. 2001;  911 96-100
  CrossrefPubMedGoogle Scholar
• 26 Rüther E, Glaser A, Bleich S, Degner D, Wiltfabg J. A prospective PMS study to validate the sensitivity for change of the D-scale in advanced stages of dementia using the NMDA-antagonist memantine.  Pharmacopsychiatry. 2000;  33 103-108
  Article in Thieme ConnectPubMedGoogle Scholar
• 27 Sternbach H. The serotonin syndrome.  Am J Psychiat. 1991;  148 705-713
  PubMedGoogle Scholar
• 28 Stieg P E, Sathi S, Warach S, Le D A, Lipton S A. Neuroprotection by the NMDA receptor-associated open-channel blocker memantine in a photothrombotic model of cerebral focal ischemia in neonatal rat.  Eur J Pharmacol. 1999;  375 115-120
  CrossrefPubMedGoogle Scholar

Koichi Nisijima, MD

Department of Psychiatry

Jichi Medical School

Minamikawachi-Machi

Kawachi-Gun

Tochigi-Ken

329-0498

Japan

Phone: +81-285-58-7364

Fax: +81-285-44-6198

Email: psychiat@jichi.ac.jp